Editorial: Stem cell follies: Crank up the spin machine
By Sacramento Bee,
Sacramento Bee
| 07. 17. 2005
Just a half year into its troubled existence, California's stem cell research institute has already spent more than $2 million, none of it on research. Alert members of the institute's 29-member oversight board are starting to ask an important question: Where the heck is this money going?
Despite a cash-flow shortage caused by a pair of costly lawsuits, institute chairman Robert Klein II has been spending freely. Four months ago, under Klein's direction, the institute quietly hired Edelman, which bills itself as the "world's largest independent public relations group," at a rate of $27,550 a month. Edelman replaced Redgate Communications, which had already racked up $108,000 in PR work in three months.
Klein didn't use a competitive bidding process in retaining either of these companies. Neither did he seek competitive bids before he hired the law firm of Remcho, Johansen & Purcell for $320,000. At the moment, he and institute President Zach Hall are negotiating a long-term contract with Edelman that could top $500,000.
Oversight board members learned of these expenditures at a meeting in Irvine last Tuesday, and some...
Related Articles
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Ed Pilkington, The Guardian | 06.12.2026
Desperate US parents paying up to $20,000 a session for a procedure scientists say could be bogus
Autistic children as young as 18 months old are being injected with human stem cells derived from umbilical cords in unapproved, unproven and...
By Tobi Thomas, The Guardian | 06.10.2026
The UK’s stem cell transplant system is potentially putting the lives of blood cancer patients at risk as a result of inadequate infrastructure and a lack of long-term planning, a parliamentary report has found.
A hematopoietic stem cell transplant, often...